A new study has found that a drug used to treat obesity can help teenage patients lose weight.
The study, published in the New England Journal of Medicine, looked at the effects of the drug liraglutide in teenagers aged 12 to 17.
Liraglutide is a GLP-1 receptor agonist, which means it helps the body to release less glucose and to feel fuller for longer after eating.
The study found that, after 56 weeks of treatment, those who took liraglutide had lost an average of 5.5% of their body weight, while those who took a placebo only lost 1.1%.
The study also found that liraglutide was associated with improved measures of insulin resistance and beta-cell function, both of which are key factors in the development of type 2 diabetes.
Currently, there are no approved treatments for obesity in teenagers in the United States.
The findings of this study suggest that liraglutide could be a safe and effective option for teenage patients who are struggling to lose weight.
If you or someone you know is struggling with obesity, talk to your healthcare provider about the potential benefits of liraglutide.
A once-a-day pill that helps teens with obesity lose weight and keep it off for at least a year is now available, according to a new study.
The medication, liraglutide 3 mg, sold under the brand name Saxenda, was recently approved by the U.S. Food and Drug Administration for use in teens ages 12 to 17.
In the new study, published in the journal Pediatrics, researchers found that among a group of teens with obesity who were given the drug for 68 weeks, those who stuck with the treatment lost an average of about 13% of their body weight.
That’s compared to just under 3% weight loss in a group of teens who were given a placebo.
What’s more, the teens who took liraglutide were more likely to see improvements in their cholesterol and blood sugar levels than those who didn’t take the drug.
“This is the first medication that we have that’s been specifically indicated for the treatment of obesity in adolescents,” said Dr. Scott Kahan, a spokesman for the Obesity Society and director of the National Center for Weight and Wellness in Washington, D.C.
“It’s a big step forward.”
The new study adds to a growing body of research on liraglutide, which was first approved by the FDA in 2014 for use in adults with obesity.
Previous studies have shown that the drug can help people lose weight and keep it off for at least a year.
Side effects of the drug include nausea, vomiting, diarrhea, constipation, and low blood sugar levels.
Liraglutide is also not recommended for people with type 1 diabetes, as it can cause diabetic ketoacidosis, a serious complication that can lead to coma or death.
The new study was funded by Novo Nordisk, the maker of Saxenda.